Monitor upcoming Phase 2 data for OV329 in focal onset seizures (expected Q2 2026) and OV4071 proof-of-mechanism results from ketamine challenge study (H2 2026). Strong cash runway reduces near-term dilution risk, but no revenue means stock will move on clinical catalysts.
Price Chart
Executive Summary
Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a year ago, with zero revenue. Key pipeline catalysts include Phase 1 dosing of OV4071 and advancement of OV329 into Phase 2 and new pediatric indications, supported by a $165.6M cash runway into 2029 after recent PIPE and warrant exercises.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $17.0M vs $10.2M in Q1 2025; EPS -$0.12 vs -$0.14
- Revenue $0 vs $130K in prior year (no product sales)
- Cash, equivalents and marketable securities $165.6M at March 31, 2026
- Raised $60M gross in March 2026 PIPE; $53.9M from Series A warrant exercise
- Advanced OV329: 9mg cohort cleared; Phase 2 in focal onset seizures expected Q2 2026
- Initiated Phase 1 for OV4071 (KCC2 activator) in healthy volunteers in May 2026
- Expanded OV329 development into tuberous sclerosis complex (TSC) and infantile spasms (IS)
Financial Impact
Net loss widened by 66% to $17M; cash position strengthened by $75M from capital raises
Risk Factors
- Clinical trial failure or safety issues with OV329 or OV4071
- Dilution from future equity offerings despite current cash position
- No approved products or revenue; cash burn rate increasing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292680 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 144 | $2.89 | awaiting T+60 | — | $2.15 (−25.43%) |
Jul 8, 2026 15w ago | 8-K | $2.73 $2.49 | ▼ −8.79% | ▼ −11.10% | $2.15 (−21.06%) |
Jun 3, 2026 20w ago | 8-K | $2.39 $2.93 | ▲ +22.59% | ▲ +20.10% | $2.15 (−9.83%) |
May 12, 2026 23w ago | Press Release | $2.87 $2.65 | ▼ −7.67% | ▼ −12.05% | $2.15 (−24.91%) |
Apr 27, 2026 26w ago | EFFECT | $2.69 $2.38 | ▼ −11.52% | ▼ −16.30% | $2.15 (−19.89%) |
Apr 21, 2026 26w ago | S-3 | $2.66 $2.44 | ▼ −8.27% | ▼ −13.05% | $2.15 (−18.98%) |
Apr 20, 2026 27w ago | 8-K | $2.89 $2.49 | ▼ −13.84% | ▼ −20.62% | $2.15 (−25.43%) |
Mar 18, 2026 31w ago | 8-K | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers